Related Experiment Videos
Pharmacokinetics of teicoplanin in pediatric patients
1First Infectious Diseases Clinic, University of Genova, G. Gaslini Institute, Italy.
Insights
This study investigated teicoplanin pharmacokinetics in pediatric patients aged 2-12 years. Teicoplanin demonstrated a long terminal half-life and primarily renal clearance, with no adverse effects observed.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Pharmacy
Background:
- Teicoplanin is an important antibiotic for treating Gram-positive bacterial infections.
- Understanding teicoplanin pharmacokinetics in pediatric populations is crucial for optimizing dosing and ensuring efficacy.
- Limited data exists on teicoplanin's pharmacokinetic profile in children.
Purpose of the Study:
- To characterize the pharmacokinetic profile of teicoplanin in pediatric male patients.
- To evaluate teicoplanin's safety and tolerability in this age group.
- To compare pediatric pharmacokinetic parameters with those of adult volunteers.
Main Methods:
- A single intravenous dose of 3 mg/kg teicoplanin was administered to 13 pediatric patients (2-12 years old).
- Blood and urine samples were collected over 8 days post-administration.
- Teicoplanin levels were quantified using microbiological assay, and pharmacokinetic parameters were analyzed using compartmental and non-compartmental methods.
Main Results:
- The terminal elimination half-life of teicoplanin averaged 57.9 hours.
- Volume of distribution at steady state was 0.80 L/kg, and total clearance averaged 14.8 mL/h/kg.
- Renal clearance accounted for approximately 60% of total clearance, with 59% cumulative urinary recovery over 8 days.
- No significant correlation was found between elimination half-life and age.
- No adverse reactions were reported.
Conclusions:
- Teicoplanin exhibits predictable pharmacokinetics in pediatric patients, characterized by a long terminal half-life and significant renal excretion.
- The established pharmacokinetic model and parameters are reliable for pediatric use.
- Teicoplanin appears safe and well-tolerated in children aged 2-12 years for prophylactic use.
Abstract:
The pharmacokinetics of teicoplanin have been studied in 13 pediatric male patients from 2 to 12 years of age. Patients were given a single 3-mg/kg intravenous dose of teicoplanin for prophylaxis. Blood and urine samples were collected for 8 days after administration, and teicoplanin levels were determined by microbiological assay. Pharmacokinetic parameters were estimated from a three-compartment open pharmacokinetic model and from a noncompartmental analysis. Levels in plasma 1 h after the administration averaged 14.8 mg/liter. The half-lives of the two distribution phases were 1.3 and 9.7 h. The half-life of the terminal phase averaged 57.9 h, with similar estimates obtained from the noncompartmental analysis and from data from urine. The volume of distribution of the central compartment was 0.15 liter/kg, whereas the volume of distribution at steady state and during the elimination phase were 0.80 and 1.25 liters/kg. The total teicoplanin clearance averaged 14.8 ml/h per kg, with renal clearance accounting for about 60% of the total. The average cumulative recovery of teicoplanin in urine over 8 days was 59% of the dose, similar to the value obtained in adult volunteers. There was no significant linear correlation between elimination half-life and age. Preliminary data after repeated administration support the reliability of the model used and the validity of the mean estimated parameters. There were no local or systemic adverse reactions to teicoplanin.